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1. Introduction
Proteins are linear covalent chains of amino acids. In most proteins, the chain winds in a specific
way to adopt a set fold, or “conformation”, that is stable and that allows it to function. A
number of proteins remain unfolded in their native state and these are referred to as intrinsi‐
cally disordered proteins. These unfolded proteins remain soluble and functional and some
exhibit specific ligand binding capability, which can cause them to adopt an induced fold. In
contrast to these two functional situations of natively folded and disordered proteins, proteins
that are normally folded or disordered can misfold, that is, to fold incorrectly.
Proteins may misfold as a result of enzymatic cleavage, post-translational modification,
mutation, overabundance or structural destabilization due to alteration in the tissue environ‐
ment. Accumulation of misfolded proteins can occur more readily when proteostasis mecha‐
nisms that foster correct folding of proteins, such as the chaperone system, and that clear the
cell of misfolded proteins, such as the ubiquitin-proteasome system, are compromised [1]. A
subset of human proteins appears to have an unusual tendency to misfold and this is recog‐
nized as a central event in a number of human diseases (reviewed by [2]). Improper folding
often leads to problems because the misfolded protein cannot perform its normal role (loss of
essential function) and because it assembles into oligomeric forms or larger aggregates that
are toxic to the cell (gain of harmful function) [3]. The most recognized misfolded conformation
is a stacking of β-sheets forming a crossed-β secondary structure that assembles into a linear
multimeric fiber called amyloid (reviewed in [2]).
Several neurodegenerative diseases share protein misfolding as an underlying cause [4, 5].
These diseases can be classified based upon the proteins affected [3] while sharing a com‐
mon mechanism of emergence. Protein misfolding in neurodegenerative diseases has been
the focus of many reviews; excellent examples are in [5-9]. Therefore, a comprehensive re‐
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view will not be undertaken here. The canonical neurodegenerative diseases are Alzheim‐
er’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, amyotrophic lateral
sclerosis and the prion diseases. Although each involves distinct proteins, misfolding has a
common role. Huntington’s disease is caused by an excessive number of sequential gluta‐
mines near the N terminus of the protein huntingtin. An expansion of the natural glutamine
stretch exceeding approximately 33 residues results in Huntington’s symptoms and the age
of onset of the disease declines with increasing residue number [10-12]. A likely reason for
this is the increased propensity for aggregation with increasing polyglutamine length [13].
Amyotrophic lateral sclerosis is a disease associated with the death of the upper and lower
motor neurons in the spinal cord, brain stem and motor cortex. The affected neurons accu‐
mulate aggregate protein inclusions that may be causing the cells to die. Mutations in genes
encoding superoxide dismutase-1, TAR DNA binding protein 43 and fused in sarcoma/
translation in liposarcoma (FUS/TLS) are implicated in ALS (reviewed in [14]). Prion diseas‐
es display several interesting commonalities with these other neurodegenerative diseases.
Prion diseases emerge from misfolded prion protein, which serves as a template for subse‐
quent misfolding of native prion protein with ensuing aggregation and neuron loss. The
propagation of pathogenic misfolding from one protein molecule to its healthy neighbours
by templating was long considered to be unique to prions; however, recent studies have
suggested that molecular templating of misfolded proteins occurs with other neurodegener‐
ative diseases as well. Furthermore, templating is inferred by observation of their spatial
spread from select foci in the brain [5, 15, 16]. It is notable that prion diseases, which are in‐
fectious, may occur in animals or humans of all ages, whereas the apparently non-transmis‐
sible protein folding diseases occur mainly with ageing. This implies that a key step in all
protein folding disease may be the initial establishment of a misfolded protein in a neuron,
whether it is a misfolded protein taken in at any age by infection or misfolding that emerges
in a susceptible endogenous protein due to faltering proteostasis with ageing. Therefore, the
prevention of misfolding and/or the promotion of disaggregation and refolding of misfold‐
ed proteins in vivo appear to be the most direct means of dealing with all these diseases.
In this chapter, the focus is on AD and PD, as these are the two most prevalent neurodege‐
nerative diseases, and the proteins that misfold in these diseases are well studied. AD ac‐
counts for approximately two thirds of all cases of dementia [17]; it leads to cognitive
deficits in reasoning, memory, abstraction and motor skills, with eventual death. It is charac‐
terized at the molecular level by extracellular aggregates of a short peptide called amyloid
beta (Aβ, and also called beta amyloid), which can form oligomers and larger fibrils with
amyloid structure and later emerging intracellular neurofibrillary tangles that are composed
of hyperphosphorylated tau protein (reviewed in [18]). In this chapter, Aβ normally refers to
Aβ42, which is the 42-residue peptide and also appears to be most toxic form. There is in‐
creasing evidence that the Aβ oligomers have a key and likely causative role in AD. Most
compelling are studies showing mutations in the regulatory region or encoded protein se‐
quence in amyloid precursor gene in families predisposed to AD [19-21]. In contrast to AD,
PD has been found to involve the misfolding of α–synuclein (αS) into aggregates found in
Lewy bodies and Lewy neurites. PD affects the substantia nigra, a region of the brain in‐
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volved with reward, addiction and movement. Many of the onset symptoms of PD reflect
this, and the diagnosis is based on resting tremor, slowness of movement, rigidity and pos‐
tural instability [22]. These two proteins are unrelated in sequence and they have distinct
structures in their native form, with Aβ a short mainly unstructured peptide and αS a larger
140-residue protein that is post-translationally modified and that can exist in alternative
conformations including a largely α-helical form and a disordered state [23, 24]. In spite of
these differences, both proteins misfold and aggregate, and the aggregates of each can be de‐
tected and measured using assays that will be discussed in the section below.
There is growing interest in the development of protein folding modulators that would offer
to prevent or alleviate misfolding and to avoid the damage that occurs in neurodegenerative
diseases. There has been progress along several avenues, but no magic bullet to date. None‐
theless, there remains substantial untapped diversity among natural products and notably in
marine resources. With a focus on Aβ and αS, which are implicated in AD and PD, respectively,
this chapter will examine natural agents that may prevent or ameliorate protein misfolding
diseases, with particular attention to the potential of marine resources for possible discovery
and development.
2. Screening and evaluation for action on protein folding
With the recognition that protein misfolding is a cause of several neurodegenerative diseases
and a common mechanism of their progression, promising developments have begun to
emerge (reviewed in the next section). These have relied upon the measurement of protein
misfolding modulation as an early step in screening and evaluation of new active molecules
or as a follow-up step in the evaluation of known and promising candidates because of their
suspected effects on the diseases. Identification of a molecule as a folding modulator raises the
possibility that it could address the cause of AD or PD, rather than only addressing their
symptoms, which makes products identified in this way potentially valuable in prevention as
well as in amelioration of existing disease.
2.1. In vitro analysis of protein misfolding modulation
For both Aβ and αS, the transition from the native state to an amyloid conformation is not
direct, but involves steps or stages. These may include unfolding, oligomerization and further
aggregation into amyloid fibrils, with the possibility of off-pathway aggregation or reversal
of these processes [25, 26]. This is summarized in Fig. 1. Compounds may prevent misfolding
and/or templating by inhibiting the unfolding of a natively folded protein, by promoting the
folding of an unfolded form, by preventing amyloid formation or by diverting the protein
toward an alternative aggregation pathway leading to a less harmful aggregate. A selection of
assay approaches to misfolding evaluation will be compared here in terms of information
value, throughput and versatility.
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Figure 1. Overview of the general trajectory of protein misfolding with amyloid formation. Solid black arrows show
pathway toward amyloid formation and stippled arrows show pathways of prevention or reversal of amyloid and re‐
lated oligomers. This is an original diagram based upon information in reviews [2, 23].
2.1.1. Protein unfolding
For the discovery and development of novel agents against diseases such as AD and PD, a
fuller picture of the action of a compound can be obtained by investigating the distinct steps
of unfolding, aggregation, misfolding and amyloid formation. Proteins may remain largely
folded and still produce amyloid or similar aggregates, provided that a local aggregation-
prone sequence is exposed [27]. Nonetheless, for most proteins that readily form amyloid, it
appears that that the loss of native folding is a required step [27]. Both Aβ and αS appear to
have some unfolded or disordered character, but with regions that can become helical under
appropriate conditions [28-30]. Inducing or preserving this helical conformation is a rational
approach to preventing amyloid formation [29, 31, 32].
Folded and unfolded proteins differ in several characteristics that can be easily measured
and that would allow folding modulators to be detected and evaluated. Some of the most
common methods are summarized here. For example, proteins absorb right and left-circu‐
larly polarized light differently; this circular dichroism (CD) can be measured over a series
of wavelengths to give informative spectra. The CD spectra of unfolded and folded proteins
differ and those of proteins with predominantly α-helix and β-sheet secondary structure can
be easily distinguished. In more detailed studies, the proportion of each major secondary
Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century98
structure in a protein can be calculated from the spectrum using software such as DICHRO‐
WEB [33]. Moreover, diagnostic features such as minima at wavelengths of 208 and 222 nm
for α-helical proteins can be monitored in order to quantify changes in fold in response to
temperature, solution components or other factors. To date, CD has been used for small-
scale studies on protein folding and protein-ligand interaction because throughput is limited
to a single sample at a time. The recent development of a high-speed automated CD spec‐
trometer (ACD, Applied Photophysics) may allow this approach to be employed more
broadly in sample screening. An advantage of CD measurement is that it is an intrinsic
property of a protein; thus, the spectra require no additive and the protein can be measured
directly without accessory molecules or modifications. Another intrinsic feature of proteins
that can be measured directly is fluorescence. Proteins with aromatic side chains fluoresce
when exposed to UV light and this can undergo a shift in intensity or wavelength of intensi‐
ty maximum with folding. Fluorescence can also be measured using new devices that allow
miniaturized measurements in a parallel manner using a similar rapid-throughput approach
(e.g. the Optim 1000, Avacta Innovative Analysis). Likewise, differential binding of dyes
such as SYPRO Orange allow protein forms with different exposure of hydrophobic resi‐
dues to solvent to be distinguished. In the case of SYPRO Orange, the dye is quenched when
free in an aqueous solution, but it becomes unquenched when it interacts with the hydro‐
phobic regions that are exposed upon protein unfolding and its fluorescence increases as a
consequence. This measurement can be performed efficiently on large numbers of samples
using devices designed for quantitative PCR [34]. Measurements by these approaches allow
protein folding to be assessed and changes in fold and/or fold stability to be examined. An
informative and frequently employed measure of fold stability is the melting temperature
(Tm), as proteins with more stable folds normally melt at higher temperatures. The Tm can
be determined by any of the above techniques. A compound that stabilizes the folded con‐
formation of a protein would raise its Tm and this change can be easily quantified by the
above approaches. A caveat with amyloid-forming proteins is that stabilized folding, as ex‐
hibited by a higher Tm, may not necessarily represent the native folding that is assumed to
preclude amyloid formation. For this reason, CD is particularly valuable, as it also allows
the secondary structure to be determined; a spectrum distinct from that of β-sheet would
provide a reasonable indication that the stable form is native and unrelated to amyloid.
2.1.2. Amyloid-like structure
It was through dye binding that amyloid plaques were first discovered. Fibrous aggregates
in tissues stained blue when treated with acid followed by iodine and the aggregates were
termed amyloid because they were believed to be starch based upon the colour develop‐
ment (reviewed in [35]). Although it is a misnomer, the name amyloid has endured and sev‐
eral different dyes have become invaluable in the study of protein misfolding and amyloid
formation in vitro.
Thioflavin T (ThT), a benzothiazole dye, and Congo red, a diazobenzidine dye, are both
commonly used to quantify the amount of amyloid protein present in a solution. ThT was
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first described to have amyloid-binding ability over 50 years ago [36] and it has since been
in widespread use in the study of amyloidosis and the search for possible binding mole‐
cules. Congo red has also been in use for amyloid detection and quantification for several
decades since its first description in that role [37]. Both of these dyes undergo a red shift in
their fluorescence emission when they interact with amyloid fibrils. They cannot be used to
distinguish between amyloid fibrils and smaller aggregates; however, they allow quantita‐
tive analysis and they continue to find wide use in amyloid analysis. Thioflavin S is a mix‐
ture of components derived from ThT and it has no spectral shift in absorbance or emission,
which makes it suitable only for imaging and not for quantitation in solution because of
high background [35]. Derivatives of N-arylaminonaphtalene including ANS and bis-ANS
bind primarily to early stage aggregation in amyloid formation [38, 39]. They have not been
as widely used as ThT and Congo Red, but they may find greater use with the increasing
focus on aggregation pathways (see section 3 below).
Recently, there has been interest in identifying newer binding fluorophores that allow oligo‐
meric aggregates to be distinguished from fibrils. An example is the indole compound tryp‐
tophanol. It allows specific detection and quantitation of prefibrillar oligomeric Aβ because
its fluorescence is quenched only in the presence of that form of Aβ with no similar quench‐
ing in the presence of Aβ fibrils [40]. Another is the carbocyanine dye JC-1 that distinguishes
different aggregation states of αS [41]. JC-1 allows real-time tracking of αS aggregation, as
different fluorescent signals are emitted for monomer and fibrillar binding and the ratio of
the two signals allows for real-time visualization of αS aggregation [41].
Another recent development is the elaboration of antibodies and related agents that recog‐
nize proteins exclusively in their amyloid conformation, allowing the amyloid portion of the
protein in question to be detected and quantified. A monoclonal antibody raised against αS
was shown to recognize the protein in its amyloid form and, although the anticipated use is
mainly in vivo, it showed effective recognition in an in vitro ELISA format [42]. Novel anti‐
bodies, termed gammabodies, were engineered by grafting a series of peptide sequences
from Aβ into immunoglobulin variable regions [43]. These have found use in distinguishing
oligomeric and amyloid forms of Aβ and this technology would be expected to be applicable
to other aggregating proteins [43]. Since an amyloid-like structure is relevant to many dis‐
eases, a new capture and detection peptoid that behaves in a manner similar to an antibody
offers unusual versatility. This peptoid, based upon a 6-amino acid stretch in the human PrP
sequence, binds to the amyloid forms of Aβ, αS, amylin and serpin [44].
Model proteins that undergo transition to an amyloid-like conformation may also offer
alternatives for amyloid formation-related studies [45]. For example, the 37-residue natively
α-helical winter flounder (Pseudopleuronectes americanus) antifreeze protein wflAFP-6
(HPLC-6) adopts an amyloid-like structure during the freeze-thaw process [46, 47]. This may
offer an interesting model system for the study of the conversion of a protein from its native
form into amyloid fibrils [47, 48]. The ability to generate rapid amyloid formation in wflAFP-6
using the freeze-thaw process would offer low background compared with Aβ assays and the
consistent α-helical nature of the native AFP may also allow initial unfolding steps to be more
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clearly evidenced than in proteins with less defined native structure. Nonetheless, a molecule
found to be an amyloid-relevant folding modulator using AFP amyloid-like transition assays
may be universal or nearly so, as in the case of the peptoid detection system described above,
or it may be specific to the wflAFP-6 and have no effect on other amyloid-forming proteins.
Therefore, in spite of its potential advantages, further study of the antifreeze protein model
would be required before its adoption in an assay platform.
2.1.3. Protein interaction during amyloid formation
As the interaction between locally or entirely misfolded monomers appears critical to non-
native protein association, there is interest in identifying molecules that directly interfere with
that process. Therefore, assays for binding competition or impedance have been developed. A
convenient new microplate assay employs fluorescently labelled Aβ. Unlabelled Aβ is coated
onto the plate surface and then the labelled Aβ is applied in solution and allowed to bind [49].
After unbound material is washed off, the fluorescence remaining can be used to determine
the level of interaction of Aβ [49]. Although the aggregation state of the Aβ in solution or on
the plate is not indicated, the assay indicates the interaction between in-solution and on-plate
Aβ that is inhibitable, which can be taken to represent either oligomer formation or assembly
into larger fibrils. Thus, molecules that affect any part of this process can be readily identified.
Nonetheless, with the aggregation state of the binding units unclear except where Aβ frag‐
ments are used, this assay does not indicate which step(s) in assembly of the monomer-
oligomer-fibril are being affected.
Aβ oligomerization and fibril formation can be challenging to study in vitro using dyes and
other methods because of spurious background oligomer formation and the difficulty in
determining how much oligomer may already have formed in a starting sample [50]. For these
reasons, assays that avoid these problems have garnered interest. In one example, a procedure
was developed involving a semi-denaturing detergent-agarose gel electrophoresis followed
by blotting and immunological detection with an appropriate antibody recognizing the protein
in all its forms [51]. The method allows amyloid aggregate size distributions to be determined
and the user can distinguish among the monomeric, oligomeric and large aggregated (likely
fibril) forms. A drawback is that it involves a vacuum transfer of proteins from the gel to a
PVDF membrane. A derived method employing capillary blotting to a nitrocellulose mem‐
brane, reminiscent of nucleic acid blotting, has made the assay more precise and scaleable for
screening purposes [52]. These methods allow the association state of the starting material to
be determined and the effect of any product to be evaluated in comparison. Another approach
is to eliminate the possibility of aggregates in the starting solution. An example is an assay
based upon the expression of the Aβ sequence in tandem with green fluorescent protein (GFP)
as a fusion within a bacterial cell [53]. Aggregation of Aβ precludes GFP folding and so there
is no fluorescence, whereas addition of a molecule impeding the aggregation of Aβ results in
GFP folding to its native structure with consequent fluorescence. A more directly quantifiable
in vitro form of this assay was developed using the Venus yellow fluorescent protein (vYFP)
instead of GFP, which allows denaturation and refolding under precisely controlled conditions
to detect molecules that promote or inhibit aggregation [50].
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2.2. Cell- and organism-based analyses
Once an active extract is identified by efficient in vitro assay and similar assay-guided frac‐
tionation has revealed the class of molecules or the molecule that is responsible, determina‐
tion of effects in vivo is of interest. Using culture models such as the PC12 primary neuronal
cells or the SH-SY5Y neuroblastoma cell line, effects of active molecules can be determined.
In a first approach, cells can be treated by transfection or other means to harbour high levels
of the protein of interest and then the effect of active molecules on cell survival can be meas‐
ured using one of several commercially available assays for dead cells, which measure lac‐
tate dehydrogenase leakage or other indicative parameters. However, more precise
information can be gleaned by histological analysis using stains such as Congo red or thio‐
flavin S, described above, that reveal the presence of amyloid accumulation. Immunohisto‐
chemistry using appropriate antibodies against Aβ or αS can be even more informative, as
some allow distinction of oligomeric denatured forms from amyloid fibrils.
Cell-based assays can also provide an indication of the possibility of a molecule crossing the
blood-brain barrier. Although Aβ circulates in the serum [54] and αS is expressed in red
blood cells [55], it is considered preferable for a compound to have direct access to the brain
where the pathology takes place. Therefore, blood-brain barrier models in cell culture, such
as the MDR-MCCK monolayer [56], are available to predict the permeability for specific
substances. Nonetheless, blood brain barrier physiology is more complex than the models or
direct plasma/brain ratio determinations would predict [57]. For that reason, results must be
interpreted with care.
Animal models provide critical understanding in terms of the distribution, mode of action and
effectiveness of an active molecule. Besides the well-known mouse models for many neuro‐
degenerative diseases, there are valuable invertebrate and fish models. An αS-transgenic
Drosophila fly model is available for PD [58] and an Aβ-transgenic model for AD [59] The
nematode worm, Caenorhabditis elegans, can be used to study AD and PD [60, 61]. Zebrafish
(Danio rerio) have an Aβ protein precursor-encoding gene [62] and synuclein genes have been
identified in this species [63]. Zebrafish may also become informative for studies of αS once
the encoded proteins in this organism are better understood.
3. Protein folding modulators from common terrestrial natural products
A large number of molecules have been shown to influence the aggregation of Aβ [18] and a
growing number have shown effects on αS (discussed below). Although no effective thera‐
py for PD or AD has emerged to date, progress on a number of natural products is encour‐
aging. This situation is not surprising, as synthetic and combinatorial chemistry normally
rely on a limited number of structural scaffolds and random permutations of structures and
synthesizable units [64]. In contrast, natural molecules are highly diverse and they have
been subject to evolutionary pressure under distinct conditions in which valuable activities
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have been selected. Therefore, they may offer a combination of variety and biological pre-
selection that may make a therapeutic activity more likely [64].
3.1. Natural protein folding modulators from terrestrial sources
Several natural molecules have garnered interest because they modulate amyloid formation
by Aβ (reviewed in [18, 65, 66]). A number of salient examples involving Aβ and αS are
presented here.
3.1.1. Curcumin
Curcumin is a natural polyphenol found in the traditional Indian spice turmeric. This molecule
has been extensively investigated, in part because of its role in traditional Ayurvedic medicine
[67]. Numerous studies have shown curcumin to have wide ranging biological activities,
including Aβ folding modulation. Curcumin shows promising interaction with Aβ. For
example, using an oligomer-specific antibody for immunoblotting, cucurmin was found
prevent Aβ oligomerization and toxicity in vitro. In the same study, curcumin was shown to
bind to amyloid plaques in brain sections of mice transgenic for the human amyloid precursor
protein [68]. In addition, mature fibrils of the slightly shorter Aβ40 peptide were destabilized
by curcumin [68]. Curcumin and other polyphenols, including tannic acid, rosmarinic acid,
and myricetin, were shown to inhibit fibril formation and destabilized mature fibrils for both
Aβ and αS [69]. As a result, curcumin has been a component of interest in clinical trials and,
most recently the exclusive molecule in a trial for prevention of early cognitive decline and
abnormal Aβ accumulation in the brain [70]. If an effect is observed, it would be interesting to
see if it acts directly upon misfolding at the dosage used in subjects.
3.1.2. Epigallocatechin-3-gallate
In terms of bioactive molecules in traditional medicine, perhaps the most recognized is (-)-
epigallocatechin 3-gallate (EGCG) that is found in unfermented (green) tea (Camellia sinensis).
EGCG is a pleiotropic polyphenolic molecule with interesting protein folding modulation
activity. In C. elegans expressing human Aβ in muscle cells, western blotting analysis using an
anti-Aβ antibody showed EGCG to inhibit Aβ oligomerization [71]. Studies of Aβ and αS using
ThT fluorescence, electron microscopy and other biophysical methods showed interaction
with EGCG and ensuing “off-pathway” aggregation into spherical oligomers, which thereby
prevented the formation of typical aggregation intermediates and amyloid fibrils by both
proteins [25]. Further investigation revealed EGCG to bind directly to the β-sheet structure in
the amyloid fibrils formed by Aβ and by αS and to direct their rearrangement into smaller
non-toxic protein aggregates [26]. A clinical trial is planned to examine the effect of EGCG on
early stage AD [72] and this may have effects based upon the protein folding modulation
described here, other properties of the molecule, or a combination thereof if adequate levels
are attained in the brain. Other tea compounds may offer similar protection. Theaflavins are
formed by oxidation of EGCG during the fermentation process to produce black tea. These
derivatives were shown to have similar activity to EGCG in modulating the polymerization
of Aβ and αS [73].
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3.1.3. Carotenoids and related molecules
Carotenoids (pro-vitamin A) and vitamin A are present in many commonly consumed foods.
The in vitro examination of vitamin A and β-carotene activity on AB fibril formation, as
measured using dye binding and electron microscopy suggest protective effects that appear
to result from binding to a region in the C-terminal half of the peptide [74, 75]. This is consistent
with reports that vitamin A and related molecules inhibit the progression of AD symptoms
[76]. Also using dye binding and electron microscopy, vitamin A and β-carotene were shown
to inhibit the formation of αS amyloid fibrils and to destabilize existing fibrils [77].
3.1.4. Scyllo-inositol
Another natural molecule that has garnered interest is scyllo-inositol, which is abundant in
the coconut palm (Cocos nucifera) [78]. Scyllo-inositol is a stereoisomer of myo-inositol that
stabilizes a non-toxic oligomeric aggregate of Aβ [78-80]. This is in contrast to phosphatidyli‐
nositol, which was found to promote fibrillogenesis and membrane insertion of Aβ [78]. Scyllo-
inositol also protected against Aβ oligomer-induced inhibition of long-term potentiation [80].
A clinical trial of scyllo-inositol was inconclusive after the highest doses were discontinued
[81]. Nonetheless, it remains a compound of interest provided that drawbacks can be ad‐
dressed.
3.1.5. Emerging sources
In addition to the well-studied molecules above, there are growing possibilities for other
sources of folding modulators. For example, another source of interesting polyphenols is the
wolf berry, Lycium barbarum, which is used in traditional Chinese medicine and was shown to
protect against Aβ-related cell death [82]. Extracts obtained from other species used in
traditional Chinese medicine, including cat’s claw (Uncaria rhynchophylla) and tree peony
(Paeonia suffruticosa) have shown relevant activity [83-85]. The tree peony contains 1,2,3,4,6-
penta-O-galloyl-beta-D-glucopyranose, which prevented Aβ fiber formation and reversed the
process in existing fibers [84]. In addition, other polyphenols procyanidins from apple (Malus
domestica), silymarin from thistle (Carduus marianus) and reservatrol from red grapes (Vitis
sp.) show interesting activities that may warrant further study [86-88].
3.2. Challenges with natural folding modulators
Although much attention has been brought to the natural folding modulators present in
various terrestrial species, none have yet translated into meaningful therapies. The best
prospect currently appears to be EGCG [89], which nonetheless presents challenges.
3.2.1. Challenges in delivery of natural products
EGCG is susceptible to decomposition during storage prior to being consumed, much of it may
be destroyed by normal stomach acid during digestion, it is not highly bioavailable and it
carries the possibility of hepatotoxicity (reviewed in [90]). Therefore, ideal handling, delivery
and dosage would need to be determined before this molecule could be employed successfully
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to manage disease-related misfolding in animals or humans. Nonetheless, studies have
suggested that the use of green tea is negatively correlated to the prevalence of cognitive
impairment [91] and that tea shows a dose-dependent effect in protection from PD [92].
Therefore, even with regular storage, preparation and consumption of tea as part of a normal
diet, it appears that tea components, and likely EGCG or its derived theaflavins, have a
measure of benefit. It is not yet clear whether the reported benefits involve the modulation of
protein misfolding, and this would be an area for future study. Curcumin presents challenges
similar to those of EGCG and derivatives. Dietary ingestion of curcumin appears sufficient to
offer some measure of protection from neurodegenerative diseases in populations that
consume it (reviewed in [93]), suggesting its bioavailability. Yet, bioavailability was found to
be limiting and work has been undertaken toward improving delivery of curcumin by
combining it with phosphatidyl choline, olive oil and stearic acid [94]. Similarly, plasma levels
of EGCG following oral consumption were higher when the product was encapsulated in
chitosan nanoparticles [95]. The promising suggestion is that formulation and delivery may
be optimized to enhance availability of these protein folding modulators in vivo. Other
compounds such as carotenoids are bioavailable and cross the blood-brain barrier as well,
possibly making them convenient for the establishment of protein folding modulators [96].
3.2.2. Requirement for crossing the blood-brain barrier
It is widely accepted that molecules must cross the blood-brain barrier in order to have relevant
biological effects on neurodegenerative diseases; however, interesting new findings are
suggesting that this may not always be the case. In a study using radiolabeled Aβ40 adminis‐
tered to the brains of rats, elevated peripheral Aβ40 levels reduced protein clearance from the
brain [97]. Conversely, a decline of Aβ levels in blood plasma can lead to cognitive improve‐
ment, presumably by reducing Aβ levels in the brain [98, 99]. Furthermore, genetic study of
the presenilin gene encoding a secretase with a role in Aβ synthesis revealed a heritable
expression level in the liver, suggesting a role of liver-expressed protein in brain Aβ levels
[100]. Follow-up investigation using ST571, a drug that lowers peripheral Aβ levels but that
does not cross the blood-brain barrier, showed reduction in brain Aβ [100]. Although these
were studies of complete Aβ levels rather than the different conformations and aggregates,
together they do imply that modulation of peripheral oligomerized and fibrillar forms of Aβ,
which would facilitate clearance, could affect the brain ratios of differently associated Aβ
forms. Therefore, protein folding modulators that do not cross the blood-brain barrier may
still be worth considering in the prevention and treatment of disease. These studies have the
drawback of assuming a stable and functional blood-brain barrier over the course of these
diseases; however, other findings suggest that functioning of the blood-brain barrier may
become compromised over the course of AD and other neurodegenerative diseases (reviewed
in [101]), which may result in inappropriate dosages of molecules from plasma. Therefore, the
prevention phase may be critical to the benefit of any molecule that acts peripherally to
modulate Aβ, as that is the point at which normal transfer of molecules such as Aβ across the
barrier can occur. Alternatively, the compromised blood-brain-barrier during the disease
phase may allow therapeutic molecules to reach the brain more efficiently. These possibilities
require further study.
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4. Marine possibilities for natural protein folding modulators
Natural products from the land include promising as sources of novel protein folding
modulators for the reasons outlined earlier. By extension, marine sources may hold propor‐
tionally greater opportunity for discovery than their terrestrial counterparts because, until this
decade, much of the ocean biota was unexplored. The Census of Marine Life uncovered
remarkable and previously unknown plant and animal biodiversity in the oceans (reviewed
in [102]). In the Gulf of Maine alone, the current species count identifies at least 652 fish species,
184 species of birds, 733 different species of microscopic plants and algae and 32 mammalian
species [103]. Microbial diversity is also extensive worldwide, as inferred from the large
number of new protein families uncovered from marine microbes [104].
Marine resources offer largely untapped diversity that may offer new options for natural
product development [105]. Only six marine natural products and 14 synthetic compounds
based upon the structures of natural marine products are FDA-approved agents or in clinical
trial (reviewed in [106]). However, this list is likely to grow. In 2010, 895 new citations were
reported on marine-derived compounds [107]. Marine species are already being examined for
molecules that inhibit β-secretase 1, an enzyme that processes the amyloid precursor protein
to give Aβ and other fragments [108]. Nonetheless, the development of inhibitors has been
very difficult elsewhere [108] and there may be other biological consequences to the modula‐
tion of this enzyme. Therefore, it is ideal to focus more specifically on protein misfolding, which
appears to be the linchpin in most of the neurodegenerative diseases. There is a wide variety
of challenging and variable marine environments that would naturally select for traits that
include protein folding modulation due to temperature or pressure, chemical defense mole‐
cules and other products that may be undersampled or undiscovered because of accessibility.
Marine plants and sessile marine animals may produce chemical defenses that are remarkable
in comparison to those of species that can move away from danger. In addition, species that
inhabit highly variable or extreme environments, such as freezing waters, have adaptations to
maintain proteostasis during exposure to extreme temperatures and solution properties
[109-111]. For these reasons, they may represent ideal sources of natural molecules to prevent
or ameliorate protein misfolding.
The discovery, characterization and production of marine-derived molecules appears prom‐
ising, but with complexity and risk, nonetheless. A general overview of the process is shown
in Fig. 2.
4.1. Natural protein folding modulators from marine sources
4.1.1. Marine polyphenols
Polyphenols are abundant and varied in marine algal species (reviewed in [112]). Like their
terrestrial counterparts, algal polyphenols have shown folding modulation of Aβ. The brown
seaweed (macroalgae) Ecklonia cava is found in the waters around Japan and Korea, where it
is used as a herbal remedy. A butanol extract from E. cava has been shown to prevent produc‐
tion and aggregation of Aβ and to reduce amyloid plaques [113]. Electron microscopy showed
Using Old Solutions to New Problems - Natural Drug Discovery in the 21st Century106
the Aβ oligomers to be reduced and dye binding as well, indicating an inhibition of fibril
formation. The polyphenolic phlorotannins are considered to be the active compounds
responsible for the biological activities of E. cava [114, 115]. Nonetheless, other molecules
cannot be strictly ruled out [113].
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Figure 2. Schematic summary of key steps in the identification and development of marine-sourced protein folding
modulators. Blue boxes are steps involved in discovery and characterization of protein folding modulation and the
molecule responsible. Green boxes are steps involved in production of the molecule (or of an extract containing it). For
more detail, see chapter text. Structural elucidation is not included here as it is not covered in this chapter; it is covered
in another chapter of this book.
4.1.2. Marine carotenoids
Marine algae and invertebrates harbour large quantities of carotenoids. This is of interest be‐
cause, as noted above, carotenoids are among the molecules showing promise in modula‐
tion of protein misfolding. Algal carotenoids are widely varied (reviewed in [112]). These
appear to be particularly accessible through enzyme-assisted extraction (reviewed in [116])
and they may have interesting activities. Shrimp and crab processing wastes are also excel‐
lent sources of carotenoids. Crustacean shells left over during processing contain the carote‐
noid astaxanthin (reviewed in [112]), which gives them their striking colour. This is in
addition to the chitin in the shells, and its component glucosamine, which is well known in
other contexts. There are no reports of evaluation of marine-derived carotenoids in protein
folding modulation, as there are for terrestrial counterparts. With the numerous and varied
sources of marine carotenoids, these could be compared with terrestrial versions previously
reported to modulate protein folding.




There is a plethora of marine toxins with distinctive neurological effects. These toxins are
mainly known for the poisoning risk they carry. Nonetheless, a few of them have valuable
biological activities as research chemicals and one has intriguing effects relative to AD. Using
cell-based assays, the toxin 13-desmethyl spirolide C from the dinoflagellate Alexandrium
ostenfeldii was shown to reduce Aβ accumulation in cells by just over 40% [117]. The antibody
used (6E10, Covance) detects Aβ without distinguishing between monomeric or oligomeric or
fibril forms. It would therefore be valuable to repeat these analyses using fold-specific anti-
Aβ antibodies or another fold-sensitive method to see if any effect there could be detected.
Otherwise, it may act on Aβ in other beneficial ways that would also be of interest.
4.1.4. Marine-sourced chemical chaperones and conflicting results
A variety of chemical chaperones, which are loosely defined as small molecules that promote
folding of many proteins, have gained interest in terms of wide-spectrum protection of proteins
from misfolding (reviewed in [118]). In marine species faced with protein misfolding risk, the
accumulation of one or more chemical chaperones is a common adaptation because these small
chaperoning molecules promote general proteostasis [111, 119]. Therefore, at first glance, these
molecules would appear to be ideal in terms of proteins such as Aβ and αS. They could be
produced naturally or synthetically, depending upon their molecular features, and they may
stabilize many different proteins. However, some chemical chaperones may have problematic
effects with respect to amyloidotic protein misfolding. Glycerol at supraphysiological concen‐
trations (molar range) and trimethylamine oxide (TMAO) at moderate concentrations were
both shown to favour the transition of Aβ from its unfolded conformation to the β-sheet form
requisite for fiber formation [120]. Protofibril to fibril conversion was also enhanced [120]. The
situation appears more complex for αS, with elevated concentrations (molar range) of TMAO
favouring a partially folded form with high propensity for fibril formation and even higher
concentrations of TMAO favouring an oligomeric α-helical conformation [121], which may be
consistent with a native α-helical form of the protein that resists misfolding [29]. Although
these chaperone concentrations used were far in excess of those that would be reached in
vivo, the effects suggest a possibility to be aware of if a novel folding modulator appears to be
non-specific. Stabilization by chemical chaperones may bring an increased risk of aggregation
for some proteins [119]. Furthermore, stabilization of a wider range of cell proteins or protein
complexes may cause unanticipated problems. Therefore, examination of unusual and off-
target effects would be prudent in the evaluation of chemical chaperones.
4.2. Sources for marine products
A challenge presented by many rare or remote marine species that may produce pharmaceut‐
ical or nutraceutical molecules is the difficulty in obtaining sufficient product in a sustainable
manner, from both the environmental and economic standpoints [122]. Options for these
products include the development of culture methods for the species or synthesis of the
molecule, although in many cases the molecules are too complex to be efficiently synthesized
[122, 123]. In contrast, an advantage for nutraceutical or drug development from many
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accessible marine species, both plant and animal, is that they are already supplied as human
food sources. Additionally, a large number of marine species are currently farmed, and
availability of a standard supply for natural product development would be more straight‐
forward and predictable than it would be for their wild counterparts. Sustainable production
or harvesting of species for natural marine products would be a key consideration in produc‐
tion of folding modulators, just as it is for the production of foods.
In the case of some seaweeds, marine harvesting can be carried out. However, on-land
cultivation offers the additional benefits of ideal traceability and process control, albeit with
substantial costs [124]. For microalgae, this would be the only option. Algal processing wastes
are significant and they are of interest for the development of by-products [125].
For commercially fished animal species, processing for food production is a frequent practice.
These wild finfish and shellfish species, as well as those grown in aquaculture, can generate
substantial waste during processing for food production and this waste often go to landfills
or composting. The identification of valuable properties or activities in waste materials allows
them to be used to produce co-products and, with green chemistry initiatives, these could be
produced in a sustainable fashion from a healthy wild harvesting or aquaculture operation.
There is growing interest in co-product development, as highlighted by two contrasting
examples. Snow crab (Chionoecetes opilio) are fished across the Maritime provinces of Canada.
Crab processing waste currently contributes to landfills, but the potential for additional
product development with the identification of sufficiently valuable uses is being considered
[126] as is the case elsewhere, likely based upon chitin but possibly upon other products as
well. Innovative solutions to waste challenges are also being pursued in salmon aquaculture.
Integrated multi-trophic aquaculture of Atlantic salmon (Salmo salar) with macroalgal species
and mussels (Mytilus edulis) in the Bay of Fundy, Canada, minimizes waste accumulation by
allowing nutrient and resource recovery with diminished impact on the local environment and
this process is advancing toward commercial production [127]. The economic viability of this
integration initiative will rely upon the development of foods along with other high-value
products from the cultured species [128]. A neuroprotective protein folding modulator from
such a resource could enhance markets for the food, while offering the possibility of producing
sustainable nutraceuticals and eventual pharmaceuticals as co-products if appropriate.
5. Conclusions
With protein misfolding identified as a causative event in multiple neurodegenerative diseases
and with no definitive means of prevention or cure in place, the progress being made in the
discovery and development of natural protein misfolding modulators is of great interest.
Although several promising leads from terrestrial sources have been identified, none have
been shown to provide a clear result in disease outcome to date. Therefore, while current
products are being developed and refined, it would be logical to investigate a wider range of
sources for protein folding modulators. In this context, marine species deserve a second (or,
in some cases, a first) look.
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There has already been extensive work on marine molecules from some sources, but crucial
to the proposed endeavour is screening for the most relevant activities. For example, testing
marine molecules or extracts for effects in model Aβ or αS cell survival assays may not indicate
protein folding modulation. However, the reverse is likely to be true in most cases. In other
words, appropriate protein folding modulation activity should lead to enhanced cell survival.
It is also important to be mindful of assay subtleties. Testing for anti-fibrillization activity may
uncover molecules that cause toxic oligomers to accumulate instead of amyloid fibrils, leading
to increased pathology instead of amelioration. Similarly, searching for molecules that bring
about a reduction in total Aβ (or αS) may not be prudent, as we have little understanding of
the normal roles of these proteins in the brain and therefore drastic reduction in levels may
have undesirable consequences [18]. For these reasons, an assay suite that allows determina‐
tion of toxic oligomers as well as other (non-toxic) oligmers, monomers, amyloid fibrils and
other aggregates would be ideal. In order to identify a marine extract or molecule that provides
protective protein folding modulation, the spectrum of its effects on protein misfolding and
association protein would need to be investigated. Furthermore, because a number of natural
molecules appear to affect the misfolding trajectories of both Aβ and αS, these would be of
particular interest because of the potential for wider-ranging protection from toxic misfolding.
In closing, examination of marine biota for protein folding modulators using a suitable suite
of assays may offer a promising opportunity to identify a safe, effective and sustainable protein
folding modulator that addresses the cause of a neurodegenerative disease. The untapped
diversity of marine species combined with a rational selection of assays for folding modulator
identification based upon examples used in terrestrial investigations and coupled with
appropriate downstream in vivo analysis would be ideal. For proteins such as Aβ and αS, which
form similar amyloids and can even cross-seed in spite of their structural differences [129], a
further tantalizing prospect would be the identification of a molecule that would be effective
for both AD and PD. Given the paucity of treatments currently available, discovery of an active
molecule from a marine resource could bring hope at this time.
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